THOXF (Bioporto AS) Marketable Securities: $0.00 Mil (As of Dec. 2025)


THOXF Bioporto AS THOXF
68 GF Score
Price $0.15
GF Value $0.16
! 3 Warning Signs
View Full Analysis

What is Bioporto AS Marketable Securities?

Bioporto AS THOXF 68 Marketable Securities is $0.00 Mil as of Dec. 2025. GuruFocus rates THOXF with a GF Score™ of 68/100 and a GF Value™ of $0.16. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Bioporto AS's Marketable Securities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Bioporto AS  (OTCPK:THOXF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Bioporto AS Marketable Securities Related Terms

Bioporto AS Marketable Securities Historical Data

* Premium members only.

The historical data trend for Bioporto AS's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS Marketable Securities Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
THOXF
68GF Score
Bioporto AS THOXF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioporto AS Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Bioporto AS (THOXF) has a Marketable Securities of $0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bioporto AS and its competitors.
Is Bioporto AS's Marketable Securities too high?
Bioporto AS's current Marketable Securities is $0.00 Mil. Overall, Bioporto AS has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Marketable Securities compare to TMO and DHR?
Bioporto AS's Marketable Securities of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bioporto AS and its competitors. Bioporto AS's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Marketable Securities of $0.00 Mil. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.9% below its estimated fair value. The current Marketable Securities is $0.00 Mil. Bioporto AS's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Marketable Securities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (THOXF) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of $0.15 is trading 6.9% below its estimated GF Value™ of $0.16.

Key valuation signals for THOXF:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $0.16 vs. price of $0.15 (6.9% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Other Exchanges BIOPOR:Denmark
Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
68GF Score

Get the complete analysis for THOXF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.16
GF Value